3.2.1 Indication Background ............................................................................. 3.2.2 BMS-986226 ............................................................................................ 3.2.2.1 Pharmacology of BMS-986226 ....................................................... 3.2.2.2 Toxicity of BMS-986226 ................................................................. 3.2.2.3 Nonclinical Metabolism and Pharmacokinetics of BMS-986226 ... 3.2.2.4 Clinical Pharmacology and Safety ................................................. 3.2.2.5 Pharmacokinetics of BMS-986226 ................................................. 3.2.3 Nivolumab ................................................................................................ 3.2.3.1 Pharmacology and Mechanism of Action of Nivolumab ................ 3.2.3.2 Clinical Pharmacology and Safety of Nivolumab ........................... 3.2.4 Ipilimumab ............................................................................................... 3.2.4.1 Pharmacology and Mechanism of Action of Ipilimumab ............... 3.2.4.2 Clinical Pharmacology and Safety .................................................